$26.62
1.10% day before yesterday
NYSE, Jan 02, 10:00 pm CET
ISIN
CA98985W1023
Symbol
ZYME

Zymeworks Inc. Stock price

$26.62
+1.52 6.06% 1M
+13.73 106.52% 6M
+0.29 1.10% YTD
+11.84 80.11% 1Y
+18.76 238.68% 3Y
-22.35 45.64% 5Y
+13.62 104.77% 10Y
+13.62 104.77% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.29 1.10%
ISIN
CA98985W1023
Symbol
ZYME
Industry

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.8b
Net debt
positive
Cash
$251.9m
Shares outstanding
75.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
14.9 | 16.1
EV/Sales
13.1 | 14.1
EV/FCF
negative
P/B
6.3
Financial Health
Equity Ratio
73.2%
Return on Equity
-36.2%
ROCE
-19.9%
ROIC
-57.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$134.5m | $124.8m
EBITDA
$-62.8m | $-53.4m
EBIT
$-70.6m | $-82.1m
Net Income
$-63.4m | $-76.7m
Free Cash Flow
$-66.2m
Growth (TTM | estimate)
Revenue
116.2% | 63.6%
EBITDA
43.9% | 52.0%
EBIT
41.9% | 31.5%
Net Income
44.5% | 37.5%
Free Cash Flow
-12.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-46.7% | -42.8%
EBIT
-52.5%
Net
-47.2% | -61.5%
Free Cash Flow
-49.2%
More
EPS
$-0.8
FCF per Share
$-0.9
Short interest
7.7%
Employees
273
Rev per Employee
$280.0k
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Zymeworks Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Zymeworks Inc. forecast:

Buy
89%
Hold
11%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
134 134
116% 116%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 62 62
3% 3%
46%
- Research and Development Expense 143 143
16% 16%
106%
-63 -63
44% 44%
-47%
- Depreciation and Amortization 7.82 7.82
20% 20%
6%
EBIT (Operating Income) EBIT -71 -71
42% 42%
-53%
Net Profit -63 -63
45% 45%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
Seeking Alpha
about one month ago
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral
GlobeNewsWire
about one month ago
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI • Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 ...
Neutral
GlobeNewsWire
about one month ago
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Evercore 8th Annual Healthcare Conference in Miami: ...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 273
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today